{"name":"Phanes Therapeutics","slug":"phanes-therapeutics","ticker":"","exchange":"","domain":"","description":"Phanes Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company has a pipeline of four drugs, all currently in Phase 1 clinical trials, including Peluntamig (PT217), Mavrostobart (PT199), Spevatamig (PT886), and a combination therapy with Pembrolizumab, Carboplatin, and Pemetrexed.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQRnYzbkJmaGZ2MzY0d3lGc1FVTUxvT3ZGODJ5ZThwYXN3QWxFNnkyS0JaQjRNck5QVE5UM09qVWRRbV9ZWkVzTXM3SUVWNUlQR0UwYmJLYmZEZDRzNnVtcmdkTFhFWkphRTZ0N0xvRjNxMzU4N2ZmNy1fZjltaFNFQjZqYXNwNnc1RXNWRlczaVBuQkFiYmhVR0laSEFNc1JnZ081aWhNanp6Y2JfVGN0M3JyU3JURTlwNEE?oc=5","date":"2026-04-08","type":"trial","source":"National Today","summary":"Phanes Therapeutics Expands Biliary Tract Cancer Drug Trial - National Today","headline":"Phanes Therapeutics Expands Biliary Tract Cancer Drug Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxQWlhDY1Z0VkYySzJVMzVVdHhpYklYcmxGelpYUnZkODdnWWdCM3dDT0ttX1A1OE0wOTMyUlpUdFg3Yld5MEVoVWlDYUdUS0k0S2pXRXhrdG4xd2VyMDhzb2RqdU1ZRlY5VHd5Mmw4U05pNGZQczNKSVpYcUxEMHlUblpOOGVzYWZ0QkFmNVphRGQxYTc1Z1phX3A1REdsSGcxQUoybmZOSWZJbGtZSzJiMUdPUVliV0tWOWNybm9VNHFTaE1xNVRKQjNJZm9majdWdjIyM0FaX0k4SHRlM2twSkhULS1OTnZtNHVUNFRrZl9MVkp3NGJ2QmJPZ0ZhR0ZFT1I4eURGLTB5dTB6UFc4RWFjdDFaM0hpVTZ6alVRLWNqRkRnN1BHUHQzem1ZM2JiMnpMWUJGc2J0aEMwMHE5LUZKMG9aZjUwMWFFWm5YX1d1WVU?oc=5","date":"2026-03-09","type":"pipeline","source":"PR Newswire","summary":"Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight - PR Newswire","headline":"Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQQnpjaHdQUU83c0lxY254T0c0V1FWSjVwTUtZckhxdkNVY2ZkeW1TY19rSzNaSXl0bXEwdXNCUmNVTGhGNUhUVEJBaEREdy1VU1VrU2g3dWF5YWU0ZDUzYW9XUkY1Z2lWNDJ6dlcwblliREpJNWlLMHd2S3M2UzRxTkxJa3UtZWJ4NDFBa3V2OUNwaW95MnRpcU1lMERFaGVZLUtzd2R5NzBvYTM3N0dQdXBKMHV2amJtanRtQzB6bHhoYUdudFFmSnI5T2NPdlp6OHdRb3Q5alRvdnFWOUlmcnRJbVhXVGloeWxjN2pWQ2hJNjJqTFpPbVFZdnZpeldFNUgyRlBKNXRKN2hycTVqQlpRUDJWSDNpaEZxb1ljTkVaUHBTVXVpUkJtSFhCT2hJYjNjWnVTdWttUTY1WC1OaG5kMmR5TUk?oc=5","date":"2026-01-09","type":"trial","source":"PR Newswire","summary":"Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026 - PR Newswire","headline":"Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontli","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixgJBVV95cUxQRjdTeVRtbHUzNWlrZ1dZNF9hVzdlM2c2WVQ5d25xdGtXTUVfaS1WU3FPNWV4ZzE0VGxINnhHSzMwVkRWYTVvd0hfZWlmNGlQVDhlczQtRTFuaHlIUzRpM2cxNlhhdXFxVXRzb3p4YUJCX28wUThUS04tdUt4ZkpzamtZakdMcFFLelBzTmZReUhaS1ZJaUtPbnBPd0l4QTFPQi11ajNFMXNEcFp0TUJtYzA0Rk5XdUhueGkzelR1ZkxGXzhaV3MxS01ZVFhpOTNqZmVuQWlNMXZ2N29zVE1Nek4wX3Q2X29UZUNzWmoyS3ZmMFdVbVo0LWl0Vy1wczRYd2RVSGRyTkVOaTNtUkhMRmxiY2RvcFpUMzZhTWhvLV93UnFvUkw2TUdEb1hGUkEyOHFDeUpDTkxHVl8yQndBdWhDeEtOZw?oc=5","date":"2025-12-09","type":"trial","source":"PR Newswire","summary":"Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026 - PR Newswire","headline":"Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontli","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQTjhkTEV5Nm9uUVJXbVFlLXVRQzZTckJMYjJPRVQwRXVfNTV5VU5ka3lDN21oTTNJNnhCYWV0VmplM09rQzhwVmtrQmlMNHFpX0xaa1l3WjhremV6R1dNa1gtY2ZkcnczZzExT25kT0ZPczlrUzBwOGZ0VHNyeWhrTkpIWHpBaXotV3NZcEJzeHd4TW1TVWVZUXQzaHNuTGRoT2U1eDR6NjFZRkdLN282c3JHTVNuNGl3V2gtRmM2cE8yLThISHJkZkNQYTV2bmRzb1hWUXFuY1Jwc0YxWHd6N1A1UTluNndzX3QwME1rZ0M1S19sTG9EamlqX0FvNVY5N3kwMWJLRFo1bzBVRUZPeXQ2S3diZ3Z5eUpHQkxHUTMwMDFl?oc=5","date":"2025-09-08","type":"trial","source":"PR Newswire","summary":"Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combination with chemotherapy - PR Newswire","headline":"Phanes Therapeutics announces first biliary tract carcinoma (BTC) patient dosed in clinical study of spevatamig in combi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPcGJMVExVLTRoZFhINDR1SFYyc2RzR3pOTlJSeUNsWTdyYmZHLTlVMU53alBLWTIyTVBiMzZJVkVDUk1heWRMT1JNRFhFSHpKRWZGTV9XSlQyMmtVOTRfZmlyX2RpOW9GR0F3ZFBMTEpkYTRfRGZvd291UzhhOThYc2x0a2kwQXA2VGpXMWRIZ0JfeVBLbkwzZXg3dkstWWRqNnF2M3RYY3RheHBma3JOc251SUpLbWFFb2JiUjZiU2NSQk9iZlVrWFlDaDUzWTFad3dwV19TcEtjN2dFUW9oaFZNdFdSS0xoVjBWZjdMNFhJWXViZmQ2YUxFbERiQnc?oc=5","date":"2025-05-05","type":"trial","source":"PR Newswire","summary":"Phanes Therapeutics announces first patient dosed in clinical study of peluntamig in combination with atezolizumab - PR Newswire","headline":"Phanes Therapeutics announces first patient dosed in clinical study of peluntamig in combination with atezolizumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNOXBoV3FSTEpCWDc2NWJRSVNRMVhvSHpCUmRhTWlnX2hnaW13aG5GSnF5ZGoyZmVBbUV3cFlGTVZPd25Ba0RqZDc1RUM2aTkzYlo1UFBIZW5MUzFLSDRUaHFPeDE3aXBTNFZTa2dzN2Q1M2h3Z1cxYXQwOHpHU1dfbEFRR1U4Zi1WWUZSRlJCaW1ndER1LXk0M3BLM19XUjZIbE5QU0Z3Q1B1VkNhR0w2XzJmSnk0NlQ4bXotOGNhRmVnWGF4WjBRcGhvZ1pYSmJHMVZNU0NsdV9uTENUZXlnajlMcDg5c0NKZ0J2NWpQUFBKYVRYMW9TdVpJd2s1Y283S3ZodUVWSQ?oc=5","date":"2025-02-19","type":"trial","source":"PR Newswire","summary":"Phanes Therapeutics Announces First Patient Dosed in Clinical Study of Peluntamig (PT217) in Combination with Chemotherapy - PR Newswire","headline":"Phanes Therapeutics Announces First Patient Dosed in Clinical Study of Peluntamig (PT217) in Combination with Chemothera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOMnUwSF9FTEl1MHdOUEpsbFJLTW9jbGowTm9zV0dFUFV4LW1ERU1rYUtsZXplTk5vLTdkS3FTeE9laVYtcVZoSmZrSDVxZF9fNGtGWnZRc3ZuMVB4YV9tUDI1R2VoWUMzWUZLa1d2MmhMeHNiaElqaHVWSzVLLV9Wa0pVS29DaEZZcWd3ZlJHQUZQcnQtYy1kSVY4QUhYY0FNbXpoU25QMnBrbWRMejFFSzAwNUstSnFNQWlnTDIxVG9yNEdqVW01eDB2SDk?oc=5","date":"2024-12-04","type":"regulatory","source":"PR Newswire","summary":"Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA for NEPC - PR Newswire","headline":"Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA for NEPC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxNWDdzR3V4b1dfTDFqVVAyal9PZWpPOFN5V2tZeVhZTWFONU1XczF1S1FkTkYwZ3BLVkVMMkxXSndSaXhuVFJUQkhET3ZFaXJQR3MzYTJVSy1hOXRNRy02ZGY2blRYWjBGaDJjUnZJVmZ5MTBuS19lZHJPdEE5Sk5mQ3JOU3lweFg4V2N2RzJGWGtVY1ZzZzVnLXZNcWdXN01wal9mRlpQbDNDZ0RTWmxvYW0yRGdkZUpmT0JiSkNtNzZvWk81S3NpNU56X3A1NnQteVc3ZVkzOXBjT1FMdUJ5ZDhDM0VCVHBvUmhxTEFzZkFUS2VkNnNhVmJnb0NtdEI5RE1oQldaNmswR3ozZDVNN0ZIQ0dET202VjBhVFFaMmxTOU1nSWMzZ0R2MGp2NXRxX0E?oc=5","date":"2024-01-29","type":"regulatory","source":"PR Newswire","summary":"Phanes Therapeutics, Inc. announces granting of registered trademarks for its three proprietary technology platforms by the U.S. Patent and Trademark Office - PR Newswire","headline":"Phanes Therapeutics, Inc. announces granting of registered trademarks for its three proprietary technology platforms by ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQa1ltM2Z4RFFyRDM0ZU1OaHFkdkEwNV95SzVVXzBFRWRJcUZJRW8wX2lydHExQ2JoaDlDMzQ5WVVSUmVqNWgxc0M4MzdQUjQxRGJsbFE4SUNmcWswVjRwT0gwNDNjbzBaWTVCc2F0NFNNWk1yNVVkcnJNS1czbTA1cDJ4ZzhWTlFJLTF3ajFwb1QzSXM0YTFwTDFtODllZlVqbW5iZXdybWpPRjZoRjFCQ0Rxakh5QQ?oc=5","date":"2021-05-25","type":"pipeline","source":"PR Newswire","summary":"Phanes Therapeutics Announces $40 million Series B Financing - PR Newswire","headline":"Phanes Therapeutics Announces $40 million Series B Financing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}